注:与 Thy2 组比较,*P<0.05,**P<0.01组别Thy1 组Thy2 组Thy4 组Thy5 组BRAFV600E突变[n (%) ]阴性41 (100.0)169 (96.6)4 (100.0)21 (77.8)阳性0 (0.0)6 (3.4)0 (0.0)6 (22.2)**HT[n (%) ]阴性25 (61.0)109 (62.3)3 (75.0)17 (63.0)阳性16 (39.0)66 (37.7)1 (25.0)10 (37.0)T3(μg/L)1.10±0.321.12±0.241.20±0.351.22±0.82T4(μg/L)94.74±13.7392.16±19.9089.80±16.6684.54±28.01FT3(pmol/L)4.76±0.534.83±0.774.67±0.424.80±0.58FT4(pmol/L)15.60±1.5615.66±3.0014.70±1.3015.76±4.11TSH(mU/L)2.31±1.661.95±1.295.08±6.462.83±2.11*组别Thy2 组Thy5 组HT阴性阳性阴性阳性BRAF阴性104 (95.4)65 (98.5)13 (76.5)8 (80.0)阳性5 (4.6)1 (1.5)4 (23.5)2 (20.0)192 浙江医学 2014 年第 36 卷第 3 期穿刺, 提 高诊断效 率。 ...